A large investment firm invests in venture to growth-stage startups. For their earlier stage investments, the firm will invest in medical devices, diagnostics and digital health companies. For devices and diagnostics, The firm prefers to invest in clinical-stage technologies, but will not invest in devices that require PMA approval. However, the firm is interested in regenerative medicine technologies of any stage. The firm is also interested in digital health companies at any stage. The firm is looking to invest between $5-15M for an initial investment in US-based companies.

The firm is interested in medical devices, diagnostics, digital health and regenerative medicine, but is indication agnostic within these sectors. The firm will not invest in medical devices that require PMA approval, unless they fall under the category of regenerative medicine.

The firm is a lead investor, and takes a board seat for their portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A healthcare investment firm founded in 1992 with offices in the USA actively finds and invests in life sciences companies (both public and private) that seek to cure major diseases by translating scientific innovations into positive clinical outcomes.

The firm typically makes investments ranging from $3 to $25 million depending on the target company’s stage of development and capital requirements. The firm considers investments into companies located anywhere around the globe.

The firm invests in breakthrough therapeutics, with a focus on oncology. However, the firm also considers investments into companies developing platform technologies. While the firm considers investment from seed stage to private investment in public equity, the firm’s ideal company has an asset that is pre-clinical or in early clinical trials.

The firm invests primarily in private companies but will also consider private investment in public equity opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A healthcare-focused evergreen fund wholly owned by a large Taiwan corporate seeks to participate in Series A to C rounds and is open to leading or following. Typical investments range from US$1 to 5 million, while larger investments can be considered on a case-by-case basis. The firm expects to make 4-5 new deals in the coming 12 months. The firm is currently seeking opportunities from Taiwan, the US, and Canada.

Within healthcare, the firm considers broadly across the healthcare field, including biomedicine, medical devices and diagnostics. The firm currently has an increased interest in digital health. When it comes to overseas deals, the firm prefers products that have achieved prototype and clinical proof-of-concept. The firm is opportunistic in terms of disease areas.

The firm is looking for competent and experienced management teams. As a well-networking Asia investor, the firm does not typically request regional rights, but can provide assistance with finding potential Asia partners.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A New York-based investment firm typically invests up to $6 million per investment with the ability to bring in additional LP side pocket money. The firm invests primarily in the USA but is also open to considering opportunities in Canada.

The firm only invests in oncology companies. Within the oncology field, the firm invests in proprietary technologies in therapeutics, diagnostics and devices, and is open to investing in any form of cancer (including rare cancers), but has a preference for investing in large market opportunities. The firm prefers to invest in companies that have attained proof of concept data in animals and have entered into human clinical trials.

The firm prefer to work with highly qualified, experienced management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family investment vehicle based in Australia invests in early-stage life science and digital health startups. The firm is focused on the Australian and U.S. markets with directors of the fund present in both countries. The fund is flexible in terms of investment size and capital structure and may co-invest or lead financing rounds.

The firm is interested in therapeutics, medtech and digital health companies. The group has a preference for companies that have some clinical data and is most interested in indications where the science is well-understood and the development path is straight-forward. The fund is particularly interested in repurposed and orphan drugs as well as other de-risked/accelerated regulatory pathways. The firm is most interested in ophthalmology, dermatology, microbiome-related technologies, the premature infant space and orphan indications.

The firm has a strong preference for experienced management teams, and prefers companies with modest valuations and capital needs so that their investment is impactful.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An early-stage venture capital firm is focusing on investing in behavioral health (addiction and mental health) companies. The firm is interested in digital health, services, health IT, and medical devices related to this area, and is currently looking to co-invest as part of a syndicate. The firm plans to invest in Seed and Series A rounds, with companies with proof-of-concept data. The firm will make $0.5-2.5M initial investments, and is currently focused primarily on the US, but will consider Canadian and European companies as well.

The firm will invest in services, health IT, medical device, and digital health companies that are related to behavioral health, which encompasses addiction and neuropsychiatric disorders such as (but not limited to) post-traumatic stress disorder, major depressive disorder, schizophrenia, bipolar disorder, and attention-deficit disorder. Within digital health, the firm will invest in patient or physician tools, training aids, telehealth, peer support tools, digital endpoints, and B2B platforms.

The firm is currently looking to co-invest, and may take a board or observer seat, depending on the deal size, portfolio priorities, and operational needs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global investor, exclusively focused on the development of oncology therapies, makes selective investments in early-stage drug development companies targeting cancer therapies that can bring solid proof of concept to the table. Typically, the firm invests in incorporated companies from late seed stage to early series B. The investment size will vary, and it can range from 3 to 10 million dollars with the possibility of investing lower amounts for seed stage companies. The firm may make 3-4 investments in the next year, depending on the opportunity. The firm has no geographic restriction and is actively seeking new investment opportunities across the globe.

In the life sciences, the firm is currently seeking new investments targeting the development of oncology therapies, and is open to all types of therapeutic modalities and all indications within the oncology space, including platform technology that has a lead oncology therapeutic product. The firm will typically not invest in medical devices or diagnostics, unless as companion to a therapeutic solution. Project will be evaluated on solid preclinical proof-of-concept (late preclinical stage/pre-IND or early clinical), and will often fund the companies at least up to human proof-of-concept (clinical Phase Ib – Phase IIa).

The firm only invests in private companies with experienced management teams and breakthrough potential. The firm most often takes the responsibility to be lead investor, alone or in syndicate as the opportunity demands, and wants to be actively involved in the successful development and growth of the portfolio companies. To this end, the firm has a several experts in oncology, intellectual property and drug development on the investment team and available to the portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.